Phase 3 N=100 Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
Iron Overload
Primary: Occurrence of Adverse Events — 212 Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=591 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Gastroesophageal Reflux Disease
Primary: Mean Change From Baseline to Month 12 for Hemoglobin Values — -0.29; -0.05 g/dL — p=0.042
Phase 3 N=51 Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
Bronchial Asthma
Primary: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods — 14.3; 17.1 Liters/minute — p=0.6383
Phase 3 N=276 A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)
Asthma
Primary: Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration — 0.08; 0.07 Liters — p=0.775
Phase 3 N=696 Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
Hepatitis C, Chronic
Primary: The Number of Participants Who Achieve a Sustained Virologic Response (SVR) — 153; 144; 129 participants — p=0.041
Phase 3 N=302 Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy
HIV Infections · Peripheral Neuropathy
Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline — -2.88; -2.63 score on scale…
Phase 3 N=1,050 Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 — -0.43; -0.57 Percent
Phase 3 N=1,028 A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis
Pain · Osteoarthritis
Primary: Pain Intensity Score as Measured by the 11-point Pain Intensity-Numerical Rating Scale Score at the End of the Study (Week 12 or Time of Discontinuation) — 4.3; 4.8…
Phase 3 N=226 Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
Allergy
Primary: Daily Rhinoconjunctivitis Symptom Score — 4.07; 4.14 Units on a scale (0-18) — p=0.87
Phase 3 N=10 Stem Cell Transplant for Bone Marrow Failure Syndromes
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Phase 3 N=40 Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
Bronchial Asthma
Primary: Most Frequent Adverse Events - On Therapy — 8; 8; 8; 8 Participants
Phase 3 N=8,237 Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
Infections, Rotavirus
Primary: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain — 30; 26; 56; 70 subjects
Phase 3 N=188 Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
Hypertriglyceridemia
Primary: Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of…
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 3 N=105 Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
Chronic Hepatitis B
Primary: Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52 — -3.69; -3.40 log10 copies/mL — p=<0.001